Global Financial Brief: Japan’s GDP Contraction, AI Leadership Shifts, and EU-Ukraine Funding

This update was written automatically with AI from market data and news wire reports, and published without review by a person.

Key Takeaways

  • Japan's economy unexpectedly contracted by an annualized 0.1% in the July-September quarter, marking its first decline in a year as persistent inflation and severe weather stifled consumer spending.
  • The European Commission is proposing a new €45 billion loan for Ukraine, to be financed by borrowing against the EU's shared budget, as Kyiv faces a projected €70 billion funding gap in 2027.
  • Momentum in the AI sector is shifting toward closed-model leaders like Anthropic and OpenAI following the high-profile resignation of Nvidia (NVDA) CEO Jensen Huang, which has cast a shadow over the "open-source" AI movement he championed.
  • UK-based technology firms are mobilizing to replace Palantir (PLTR) in its £330 million NHS data contract, with the government signaling a preference for "sovereign" British alternatives.
  • The US FDA rejected a Chinese-developed cancer drug from Summit Therapeutics (SMMT) and Akeso, dealing a significant blow to China’s biotech ambitions and triggering a 27% year-to-date decline for Akeso.

Japan’s Economy Faces Surprise Contraction

Japan reported its first economic contraction in four quarters as GDP fell by an annualized 0.1% during the July-September period. The result significantly missed market expectations of 0.3% growth, primarily due to a 0.3% drop in private consumption. Households remained cautious as rising living costs and record-breaking rainfall—including a 37-day streak in Tokyo—dampened consumer sentiment.

Despite the headline decline, corporate activity remained a bright spot. Business investment rose 1.6%, driven by robust demand for artificial intelligence and labor-saving technologies. However, the weak yen, trading near ¥160 per dollar, continued to inflate the cost of energy imports, further pressuring the trade balance. Following the data release, the Nikkei 225 plunged over 700 points in morning trading.

EU Proposes €45 Billion Ukraine Loan

Brussels is set to propose a €45 billion loan for Ukraine, raised through joint borrowing secured against the European Union's budget. This package is intended to cover roughly two-thirds of Kyiv's estimated €70 billion financing gap for 2027. The proposal mirrors the structure of a previous €90 billion loan, though it faces growing political friction within the bloc.

The plan requires unanimous backing from all 27 member states, but Hungary, Slovakia, the Czech Republic, and Bulgaria have signaled they will not participate in future interest payments. German Chancellor Friedrich Merz has responded by threatening to withhold agreement on the 2028-2034 EU budget unless all members contribute. EU leaders are expected to debate the linkage of Ukraine funding and the long-term budget at a summit on November 26-27.

AI Industry Braces for Post-Huang Era

The artificial intelligence landscape is undergoing a strategic realignment following the resignation of Jensen Huang from Nvidia (NVDA). Huang’s departure, linked to personal scandals and potential foreign influence concerns, has deprived the open-source AI community of its most powerful advocate. Analysts suggest Nvidia may now scale back its multi-billion dollar support for open-weight models like Meta's (META) Llama or Alibaba's (BABA) Qwen.

This downturn in open-model momentum has shifted investor focus toward Anthropic and OpenAI. Anthropic is currently preparing for a $1.4 trillion IPO, pitching a diversified hardware strategy that relies on chips from Amazon (AMZN), Google (GOOGL), and Broadcom (AVGO) alongside Nvidia. If open-source development slows, these "closed" frontier labs could gain further pricing power and market dominance.

Domestic Bids Target Palantir’s NHS Contract

In the United Kingdom, a consortium of domestic tech firms is preparing to challenge Palantir (PLTR) for the National Health Service (NHS) Federated Data Platform contract. While the government is expected to extend Palantir’s current £330 million deal for two years to avoid service disruption, ministers have initiated a new procurement process designed to favor UK tech sovereignty.

The Drystone Health AI Collaboration, a group of over 20 British companies including Voror Health Technologies, has formally announced its intent to bid. London-based Quantexa is currently viewed as the frontrunner to take over the contract in 2029. The shift comes amid intense political pressure and ethical concerns regarding Palantir’s ties to foreign military and intelligence operations.

US Regulator Rejects Chinese Cancer Drug

China’s biotech sector faced a major setback after the US FDA rejected ivonescimab, a cancer treatment developed by Akeso and licensed by Summit Therapeutics (SMMT). The regulator cited a lack of statistically significant overall survival (OS) improvement in the data provided. The drug had previously generated significant hype after outperforming Merck’s (MRK) Keytruda in earlier trials.

The rejection is the third for a China-developed therapy in recent months, highlighting the increasing difficulty Chinese firms face in meeting US regulatory standards. This regulatory hurdle coincides with proposed US Treasury restrictions on outbound biotech investments to China, aimed at protecting national security. Shares of Akeso have plummeted 27% in 2026 as investors reassess the global expansion potential of Chinese drug candidates.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top